Acurable secures £9.5m Series A funding led by Kibo Ventures to scale international distribution.
The financing round was led by Kibo Ventures to fund the global rollout of the firm's home sleep testing technology.
Acurable develops wearable medical technology designed to simplify the diagnosis and management of respiratory and cardiovascular conditions at home. The firm produces automated diagnostic devices intended to reduce clinical overhead and expand patient access.
Medical device manufacturer Acurable has secured £9.5m in a Series A financing round directed by Kibo Ventures. The capital will support the international distribution rollout of the company's flagship home sleep testing device alongside research into new diagnostic applications for chronic conditions.
The latest injection of funds follows recent commercial distribution agreements and builds upon earlier backing from existing investors including Mundi Ventures and Kindred Capital. Acurable intends to scale its presence across European territories and North America using the proceeds from the round.
From the founder
"The response to AcuPebble SA100 since its launch has been incredible, and we are thrilled to see the product being used to help patients and clinicians in the real world. This funding will help us reach our initial goal of diagnosing one million patients and gives us the opportunity to continue working on new products that will fundamentally improve the lives of millions of people living with severe chronic conditions."
Esther Rodriguez-Villegas
Professor at Acurable
Investor perspective
"We are delighted to be joining Acurable’s exciting journey. AcuPebble has the potential to transform the way sleep apnoea and other chronic conditions are diagnosed and monitored. It’s much more accurate and easier to use than other devices, and we believe it’s a huge step forward for global healthcare. This is still just the beginning for Acurable and I cannot wait for what comes next."
Sonia Fernández
Partner, Kibo Ventures
Use of funds
- 01Expand into international markets
- 02Fund research and development
